Please use this identifier to cite or link to this item:http://hdl.handle.net/20.500.12105/12709
Brain metastasis models: What should we aim to achieve better treatments?
Adv Drug Deliv Rev.2021 Feb;169:79-99.
Brain metastasis is emerging as a unique entity in oncology based on its particular biology and, consequently, the pharmacological approaches that should be considered. We discuss the current state of modelling this specific progression of cancer and how these experimental models have been used to test multiple pharmacologic strategies over the years. In spite of pre-clinical evidences demonstrating brain metastasis vulnerabilities, many clinical trials have excluded patients with brain metastasis. Fortunately, this trend is getting to an end given the increasing importance of secondary brain tumors in the clinic and a better knowledge of the underlying biology. We discuss emerging trends and unsolved issues that will shape how we will study experimental brain metastasis in the years to come.
EXPERIMENTAL MODELS | PRECLINICAL THERAPY | BRAIN METASTASIS | ORGANOTROPISM | BBB | BTB | SMALL-MOLECULE DRUGS | NANOMEDICINES | IMMUNOTHERAPY
Files in this item
- Artículo principal